Marker Therapeutics (MRKR) AI Stock Analysis

• Market Cap: $22.34M
• Dividend Yield: N/A
• Average Volume (3M): 137.12K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.68
• Revenue Growth: -12.99%
• EPS Growth: -13.67%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.10
• Shares Outstanding: 16,673,126
• 10 Day Avg. Volume: 121,728
• 30 Day Avg. Volume: 137,122
• PEG Ratio: <0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 6.43
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: -719.19K
• Enterprise Value/Revenue: -4.53M
• Enterprise Value/Gross Profit: 3.30M
• Enterprise Value/Ebitda: 1.97M
• 1Y Price Target: $9.00
• Price Target Upside: 571.64% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -1.23
• Revenue Forecast (FY): $2.68M

• Rating: 44 Neutral
• Price Target: $1.50 ▲(11.94% Upside)
• Action: Reiterated Date: 03/19/26
• Date: Action: Reiterated 03/19/26

MRKR scores low primarily due to ongoing unprofitability and sustained cash burn, despite a relatively low-debt balance sheet. Technicals also lean bearish (price below key moving averages and negative MACD). Valuation provides little support given the unusable P/E and no dividend yield data.

Positive Factors

Conservative leverage / low debt

Zero reported debt in 2023–2025 provides financial flexibility to fund clinical programs or pursue partnerships without immediate debt-service pressure. That conservatism reduces near-term solvency risk and preserves options for strategic financings over the next several months as trials progress.

Differentiated T‑cell therapy platform

A MultiTAA adoptive T‑cell approach targets multiple tumor antigens and can address both hematologic and solid tumors. That platform-level differentiation supports a broader addressable market and potential partner interest, strengthening long‑term strategic positioning in immuno‑oncology.

Recent revenue growth trajectory

Notable revenue growth in 2023–2024 indicates improving top‑line momentum—potentially from collaborations, grants, or early commercial activity—which, if sustained, can reduce near‑term financing needs, validate development progress, and support incremental investment in trials and scale.

Negative Factors

Consistent cash burn

Operating and free cash flow have been negative each year, showing a structural cash burn to fund R&D and trials. This persistent outflow forces recurrent external financing, increasing dilution risk or reliance on restrictive partnerships over the medium term.

Negative gross profit & operating losses

Negative gross profit and sustained operating losses indicate the company has not reached positive unit economics or scale. Persistently negative margins worsen financing needs and make self‑funding of development unlikely without material improvement or external support.

Poor capital efficiency (negative ROE)

Materially negative ROE across periods shows the balance sheet is not being converted into shareholder value. Weak capital efficiency heightens the risk that additional invested capital will not produce commensurate clinical or commercial returns, pressuring long‑term value creation.

Marker Therapeutics Business Overview & Revenue Model

Company Description

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

How the Company Makes Money

null

Marker Therapeutics Financial Statement Overview

Summary

Financials show persistent weakness: negative gross profit, operating losses, and net losses across the periods provided, alongside sustained negative operating and free cash flow (ongoing cash burn). The main offset is a conservative leverage profile (including periods with zero debt), but negative ROE and cash-based losses keep this component low.

Income Statement

Revenue shows strong growth in the annual history (notably 2023–2024), but profitability remains very weak: gross profit is negative in every year shown through 2024, and operating results and net income are consistently negative with deeply negative margins. The 2025 annual revenue and loss figures appear extremely large versus prior years, which increases volatility/quality-of-earnings concerns and keeps the income statement score low despite the growth trajectory.

Balance Sheet

Leverage looks conservative overall: total debt is shown as 0 in 2023–2025 (and moderate in 2020–2022), supporting financial flexibility. However, returns on equity are materially negative across all periods, reflecting ongoing losses and weak capital efficiency. Assets and equity are present, but the inability to translate the balance sheet into profits is the key weakness.

Cash Flow

Cash generation is consistently negative, with operating cash flow and free cash flow below zero each year shown, indicating continued cash burn to fund operations. Free cash flow tracks net income closely (often near 1x), suggesting limited non-cash offsets and that losses are largely cash-based. While some years show improvement in free-cash-flow growth, the absolute level remains meaningfully negative, keeping the cash flow profile weak.

Breakdown	Dec 2025	Mar 2025	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.55M	6.59M	3.31M	3.51M	1.24M
Gross Profit	0.00	-6.88M	-7.11M	-8.45M	-1.92M
EBITDA	-12.89T	-11.12M	-11.79M	-17.00M	-38.72M
Net Income	-12.16T	-10.73M	-8.24M	-29.93M	-41.88M
Balance Sheet
Total Assets	19.07T	22.02M	17.13M	34.42M	68.14M
Cash, Cash Equivalents and Short-Term Investments	16.07T	19.19M	15.11M	11.78M	42.35M
Total Debt	0.00	0.00	0.00	7.62M	11.87M
Total Liabilities	2.27T	3.46M	3.07M	14.82M	24.15M
Stockholders Equity	16.80T	18.56M	14.05M	19.60M	43.99M
Cash Flow
Free Cash Flow	-12.01T	-10.91M	-16.44M	-26.97M	-30.41M
Operating Cash Flow	-12.01T	-10.91M	-16.44M	-26.97M	-27.28M
Investing Cash Flow	0.00	0.00	18.66M	-4.95M	-3.13M
Financing Cash Flow	9.86T	14.99M	1.11M	202.13K	52.56M

Marker Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.34
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRKR, the sentiment is Negative. The current price of 1.34 is below the 20-day moving average (MA) of 1.42, below the 50-day MA of 1.61, and above the 200-day MA of 1.34, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 42.49 is Neutral, neither overbought nor oversold. The STOCH value of 19.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MRKR.

Marker Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IBIO	51 Neutral	$72.20M	-5.32	-71.26%	―	185.71%	79.03%
ADXN	51 Neutral	$6.46M	-1.12	-71.27%	―	-72.15%	-223.62%
MBRX	45 Neutral	$10.99M	-1.17	―	―	―	79.31%
MRKR	44 Neutral	$22.34M	―	-289.66%	―	-12.99%	-13.67%
ABVC	41 Neutral	$31.04M	-6.26	-88.89%	―	56.52%	75.22%
ALLR	40 Underperform	$17.37M	-2.07	-112.05%	―	―	99.82%

Marker Therapeutics Corporate Events

Marker Therapeutics Sets Date for 2026 Annual Meeting

On February 9, 2026, Marker Therapeutics, Inc. announced that its Board of Directors had set May 1, 2026 as the date for the company’s 2026 Annual Meeting of Stockholders, a move that advances the meeting more than 30 days from the prior year’s schedule and triggers specific disclosure requirements under securities regulations. As a result, the company established March 9, 2026 as the new deadline for stockholder proposals to be included in the 2026 proxy materials and directed investors to submit such proposals to its Houston corporate offices, with the record date, time and location of the meeting to be detailed in the forthcoming proxy statement.

The most recent analyst rating on (MRKR) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Marker Therapeutics stock, see the MRKR Stock Forecast page.